CD8+ T cells control HSV-1 replication in the nervous system but not the cornea in HSV-1 0ΔNLS-vaccinated mice lacking virus-neutralizing antibody

Abstract

Abstract HSV-1 is a successful human pathogen that can elicit benign pathology including cold sores to more severe to extreme life-threatening manifestations like blinding necrotizing stromal keratitis and encephalitis. To date, there is no commercially available vaccine for HSV-1 despite many failed experimental prototypes. We have evaluated the use of a live-attenuated HSV-1 strain (HSV-1 0ΔNLS) as a vaccine in a mouse model of ocular infection. This vaccine has been shown to prevent virus replication, spread, and establishment of latency while functionally preserving the visual axis and corneal integrity. The correlate of protection elicited by the vaccine is antibody, and optimal efficacy requires expression of the neonatal Fc receptor in the corneal epithelium. The present study was undertaken to determine if T cell receptor transgenic mice expressing CD8 T cells specific for glycoprotein B of HSV-1 (gBT-I.1) benefit from vaccination. gBT-I.1 mice were vaccinated with HSV-1 0ΔNLS or vehicle and subsequently ocularly challenged with HSV-1. The results showed HSV-1 0ΔNLS vaccinated gBT-I.1 mice had no measureable neutralizing antibody titer but did show enhanced survival compared to vehicle-vaccinated gBT-I.1 mice. The efficacy correlated with less infectious virus in the nervous system of HSV-1 0ΔNLS-vaccinated mice during acute infection (p < 0.05). However, viral titers and pathology were similar in the corneas of both groups. Collectively, the results suggest in the absence of antibody, vaccine-primed HSV-specific CD8+ T cells enhance control of HSV-1 replication and spread in the nervous system but are not effective in the cornea.